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Background/Aims:  The blunted ventricular systolic and diastolic contractile responses to physical and pharmacological stress in 
cirrhosis are termed cirrhotic cardiomyopathy (CCM). CCM has been known to involve multiple defects in the β-adrenergic 
signaling pathway. The aim of this study was to determine whether cirrhotic patients have blunted cardiac responses to 
catecholamine stimulation through dobutamine stress echocardiography (DSE). Methods: Seventy-one cirrhotic patients with 
normal left ventricular (LV) chamber size and ejection fraction were enrolled. The LV systolic and diastolic functions were 
evaluated by two-dimensional and Doppler echocardiography at rest and during peak dobutamine infusion (40 μg/kg/min). An 
abnormal response was defined as a decrease of less than 10% in LV end-diastolic volume, a decrease of less than 20% in 
end-systolic volume, and an increase of less than 10% in LV ejection fraction (EF) at peak dobutamine infusion, based on 
previously used criteria. The early/late diastolic flow (E/A) ratio and diastolic parameters were also measured. Results: A blunted 
LV response to dobutamine was observed in 18 of 71 cirrhotic patients (25.4%). The baseline EF was significantly higher in 18 
patients with a blunted DSE response than that of those with a normal DSE response (P<0.05). The baseline and peak E/A ratios, 
which are common diastolic dysfunction markers, were higher in the cirrhosis group than in the control group (P<0.001). No 
adverse events associated with DSE were observed. Conclusions:  Blunted cardiac responses to dobutamine stimulation, which 
are implicated in defects in the β-adrenergic signaling pathway, might contribute to the pathogenesis of CCM in patients with 
cirrhosis. (Korean J Hepatol 2010;16:376-382)
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INTRODUCTION
Coronary artery disease which makes ischemic heart disease 
or cardiac dysfunction is rare in cirrhosis.
1,2  However, most 
patients with cirrhosis have hemodynamic alterations characterized 
by increased cardiac output and decreased systemic vascular 
resistance and arterial pressure.
3,4 Despite the increased resting 
cardiac output, the ventricular contractile response to stimuli is 
attenuated, a condition termed cirrhotic cardiomyopathy (CCM).
5-7 
In  the  absence  of  consensus definitions, the  term  ‘cirrhotic 
cardiomyopathy’ is defined at present as: 1) baseline increased 
cardiac output but blunted ventricular response to stimuli; 2) 
systolic and/or diastolic dysfunction; 3) absence of overt left 
ventricular failure at rest; 4) electrophysiological abnormalities 
including prolonged Q-T interval on electrocardiography and 
chronotropic incompetence, and not all features are required for 
the  diagnosis.  Other  causes  leading  blunted  ventricular 
contractile  response  to  stimuli  should  be  ruled  out  before 
defining CCM. CCM is generally latent but unmasked when the 
patient is subjected to stress in the form of infection, exercise, 
drugs, hemorrhage, and surgery, such as liver transplantation or 
insertion of transjugular intrahepatic portosystemic stent-shunts 
(TIPS).  Clinical  features  include  structural,  histological, 
electrophysiological,  systolic, and diastolic functional abnormalities. 
Although CCM is clinically important, the screening methods 
and the prevalence of CCM are not clear yet. Many factors are Moon Young Kim, et al. Dobutamine stress echocardiography and cirrhotic cardiomyopathy  377
Figure  1.  Mechanism  of  dobutamine  stress  echocardiography 
(DSE) as a screening test for cardiac dysfunction in liver cirrhosis, 
such as cirrhotic cardiomyopathy (CCM). Heart-cell contractility 
is  determined  mainly  by  the  stimulatory  β-adrenergic  receptor 
system. When stimulated by norepinephrine or other catecholamines, 
the β-adrenergic receptor-ligand complex couples with the G-protein 
to  stimulate  membrane-bound  adenylate  cyclase, generating 
cAMP, which phosphorylates several proteins, leading to intracellular 
calcium  fluxes.  The  calcium  then  causes  actin-myosin  cross- 
linking, and thus cellular contraction. In CCM, the β-adrenergic 
receptor signaling pathway shows defects at multiple points, so 
dobutamine, an adrenergic stimulant, could not induce a myocardial 
response. 
βAR, β-adrenergic receptor; AC, adenylate  cyclase; NO, nitric 
oxide; CO, carbon monoxide; iCa, intracellular free calcium-denotes 
an  inhibitory  stimulatory  influence.
suggested as a mechanism of CCM and impaired β-adrenergic 
receptor  signal  transduction  is  one  of  them.
8,9  Hence,  we 
assumed that ventricular systolic and diastolic function in a CCM 
patient would be blunted by norepinephrine or other catecholamines 
stimulation such as dobutamine (Fig. 1). Therefore, in this study, 
we aimed to evaluate whether cardiac responses to stimulation 
by catecholamine are blunted in patients with cirrhosis through 
dobutamine stress echocardiography (DSE).
MERTERIALS AND METHODS
Patients
Seventy-one patients (60 males, 11 females) with liver cirrhosis 
were  recruited  from  the  Wonju  College  of  Medicine  Wonju 
Christian Hospital between May 2006 and June 2008. Cirrhosis 
was established by biopsy proven in 47 patients, and by presence 
of varices, laboratory data and image studies including ultra-
sonography  and  computer  tomography  scan  in  remaining 
patients. Cirrhosis was caused by alcohol in 45 patients, by 
hepatitis B virus in 12, by hepatitis C virus
 in one, by a combina-
tion of alcohol and hepatitis B virus
 in eight, by autoimmune 
hepatitis in four, and by cryptogenic in one patient. Twenty-one 
of these patients
 belonged to Child-Pugh class A, 36 were class 
B, and 14 were class C. The patients’ characteristics are sum-
marized in Table 1. All patients had abstained from alcohol for 6 
months before the study. An accurate history was recorded, and a 
complete  clinical  examination  including  chest  radiography, 
electrocardiography, pulmonary function tests, and routine labo-
ratory screening tests were carried out at the time of inclusion. 
No patient had major cardiovascular or lung disease, renal 
disease, recent gartrointestinal bleeding episodes (<15 days), se-
vere  anemia  (Hb<10  g/dL),  or  hepatocellular  carcinoma. 
Especially, patients who showed abnormal electrocardiography 
or regional wall motion abnormality, valvular heart disease in 
echocardiography were excluded at baseline enrollment. No pa-
tient took any drug that had an effect on hemodynamics
 until 
the study was completed. Eight age-and sex-matched healthy, 
non-smoking individuals with no history of cardiac or liver dis-
ease served as controls.
 They had normal results from physical
 
examinations, liver chemistry
 tests, complete blood count, chest 
radiography, and electrocardiography. The ethics committee 
of Wonju College of Medicine Wonju Christian Hospital
 ap-
proved all components of our study and patients and control sub-
jects
 provided written informed consent.
Dobutamine stress echocardiography (DSE)
Patients  and  controls  were  studied  the  morning  after  an 
overnight fasting. After a 30-min period in the supine position, 
heart rate and arterial pressure were recorded and then DSE was 
taken. In resting conditions, a two-dimensional echocardiographic 
examination  of  the  left  ventricle  was  performed  using  a 
wide-angle phased-array imaging system (General Electric, 
Vivid 7 Dimension) equipped with a 4-MHz transducer and 
recorded on EchoPAC (General Electric). A 12-lead ECG was 
also recorded with the patient at rest. Dobutamine was admi-
nistered intravenously with an infusion pump from 5 μg/kg/min 
to a peak infusion rate (40 μg/kg/min) and continued for 5 min. 
DSE was continuously monitored and recorded at rest and during 
dobutamine infusion (Fig. 2, 3).
10 With echocardiography, cardiac 
structural and functional indices such as ejection fraction (EF), 
end-diastolic volume (EDV), end-systolic volume (ESV), early/ 
late  diastolic  flow  ratio  (E/A  ratio),  interventricular  septal 
diastolic wall thickness (IVSD), left ventricular posterior wall 
diastolic thickness (PWD) at baseline and peak infusion, and 
their  percent  changes  were  estimated.  Off-line  analysis  of 
echocardiographic images was performed by two investigators 
under blinded conditions. Agreement between the two observers 
was required for test results to be interpreted as positive. In the 378  The Korean Journal of Hepatology Vol. 16. No. 4, December 2010
 
Figure  2.  Normal  left  ventricular  response  to  DSE  in  liver 
cirrhosis. (A) Apical four-chamber view at baseline. (B) At peak 
dobutamine infusion (40 μg/kg/min), the left ventricle shows a 
normal  contraction  response.
 
Figure  3.  Abnormal  left  ventricular  response  to  DSE  in  liver 
cirrhosis. (A) Apical four-chamber view at baseline. (B) At peak 
dobutamine infusion (40 μg/kg/min), the left ventricle shows a 
blunted  contraction  response.
case of  disagreement,  the  judgment of  a third  observer  was 
conclusive.
Definition
An abnormal volume and left ventricular EF response is de-
fined as a blunted DSE response with a less than 10% decrease in 
end-diastolic volume, a less than 20% decrease in end-systolic 
volume, and a less than 10% increase in EF at peak dobutamine 
infusion.
10 We also measured chronotropic response by heart 
rate (HR) reserve (HRR)={[(peak HR-HR at rest)/(220-age-HR 
at rest)]×100} and a chronotropic incompetence was defined as 
HRR less than 80%.
11,12
Variability analysis
Intra-observer  variability,  in  regard  to  calculating  left 
ventricular volume, was assessed by the investigator in the first 
30 dobutamine stress tests of this study. At baseline, the mean 
percent  variability  values  in  two  different  blind  evaluations 
performed  30  days  apart  for  end-diastolic  and  end-systolic 
volumes were, respectively, 6±4% and 6±5%. At peak stress, the 
mean percent values were, respectively, 7±5% and 7±6%.
Statistical analysis
Data were expressed as mean ± SD unless otherwise indicated. 
Comparison  of  groups  (cirrhotic  patients  with  blunted  DSE 
response, normal DSE response, and controls) were performed 
by the Mann-Whitney U test and  the Kruskal-Wallis test as 
non-parametric analysis. A P value<0.05 was considered 
statistically significant. Statistical analyses were performed with 
SPSS for Wie4ndows, version 12.0 (SPSS, Chicago, IL, USA).
RESULTS
There was no difference in general characteristics between the 
control group (M:F=7:1, mean age±S.D.; 47.0±10.9 years) and 
the  cirrhosis  group  (M:F=61:10,  mean  age±S.D.;  52.0±8.1 
years). In patients with liver cirrhosis, no difference in baseline 
characteristics  according  to  DSE  response  was  observed 
(Table 1). No complication or adverse event such as arrhythmia 
or  hemodynamic  instability  related  with  DSE  was  observed 
except a sense of palpitation along with increase of heart rate in 
eleven patients, however,  this symptom was resolved  within 
several  minutes  after  finish  of  DSE  and  discontinuation  of 
dobutamine infusion and there was no relationship between the 
development of palpitation and the results of DSE. 
Echocardiographic indices according to DSE outcome
No  significant  difference  in  echocardiographic  indices  at 
baseline and peak dobutamine infusion between control and 
cirrhosis patients was observed except baseline and peak E/A 
ratio. Baseline and peak E/A ratio, common diastolic dysfunction 
markers, were higher in the cirrhosis group than in controls 
(Table 2, P<0.001). Blunted DSE response was observed in 18 
patients (25.4%) in the cirrhosis group, however, the blunted 
response to DSE was not observed in the control group (Fig. 3). 
Therefore, cirrhosis patients were divided into two subgroups 
according to DSE outcome: a normal DSE response group (n=53, 
74.6%) or a blunted DSE response group. Baseline EF was 
significantly higher in the 18 blunted DSE response patients than 
those of the normal DSE response patients (P<0.05), however, 
both were within normal range. According to the definition of 
blunted DSE response, the change of EF, EDV, and ESV from 
A  B
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Table  1.  Patient  characteristics  according  to  dobutamine  stress  echocardiography  (DSE)  responses
Total
Liver  cirrhosis
with  normal  DSE  response  (n=53)
Liver  cirrhosis
with  blunted  DSE  response  (n=18)
P-value
Age  (yr) 52.0±8.1 52.3±8.2 51.0±8.0 0.252
Sex  (male:female) 61: 10 46:7 15: 3 0.706
Etiology  of  cirrhosis 0.969
    Alcohol 45 (63.4%) 31 (58.5%) 12 (66.7%)
    HBV 12 (16.9%) 10 (18.9%) 3 (16.7%)
    HCV 1 (1.4%) 1 (1.9%) 0 (0%)
    Alcohol+HBV 8 (11.3%) 7 (13.2%) 2 (11.1%)
    Autoimmune 4 (5.6%) 3 (5.7%) 1 (5.6%)
    Cryptogenic 1 (1.4%) 1 (1.9%) 0 (0%)
Child-Pugh  score 7.6±1.8 7.8±1.7 7.1±2.0 0.864
Child-Pugh  class 0.604
    A 21 (29.6%) 14 (26.4%) 7 (38.9%)
    B 36 (50.7%) 28 (52.8%) 8 (44.4%)
    C 14 (19.7%) 11 (20.8%) 3 (16.7%)
MELD 10.6±3.8 10.7±3.8 10.5±4.0 0.792
DSE, dobutamine stress echocardiography; HBV, hepatitis B virus; HCV, hepatitis C virus; MELD, model of end stage liver disease.
baseline to peak of dobutamine infusion in the blunted response 
group  showed  inverse  responses  compared  with  the  normal 
response cirrhotic group, and therefore EDV and ESV increased 
and EF  decreased at  peak (Table 2, P<0.001).  However, no 
significant difference was observed in other echocardiographic 
indices including structural parameters between the normal and 
the blunted DSE response cirrhosis group (Table 2).
 
Liver profiles according to DSE outcome
There  was  no  significant  difference  in  Child-Pugh  score, 
MELD score, or etiology of cirrhosis between normal and 
blunted  DSE  response  groups.  Hence,  no  correlation  was 
documented  between the severity  of cirrhosis  and the deve-
lopment of cardiac dysfunction (Table 1).
Chronotropic incompetence
Including all blunted DSE response patients, 88.6% of the 
cirrhotic patients showed chronotropic incompetence (HRR less 
than 80%) for dobutamine infusion. No significant correlation 
between the severity of chronotropic incompetence and DSE 
response  outcome  was  observed  (P>0.05).  However,  eight 
cirrhotic patients who showed paradoxical heart rate responses 
for  dobutamine  infusion  (HRR  less  than  0%)  also  showed 
blunted DSE response.
DISCUSSION
Cardiac output increases whereas systemic vascular resistance 
and arterial pressure decrease in cirrhosis. Despite the increased 
basal  cardiac  output,  the  cardiac  response  to  physiologic  or 
pharmacologic stimuli is known to be subnormal, a phenomenon 
called  ‘cirrhotic  cardiomyopathy’  (CCM).
3-7  Without  firm 
diagnostic criteria and a screening test, the exact prevalence of 
CCM remains unknown. In general, CCM does not show overt 
heart failure at rest due to an ‘auto-treating’ effect reducing 
afterload related to peripheral vasodilatation of cirrhosis and 
compensatory diminution of inhibitory influences such as the 
cardiac muscarinic system.
5,13 Therefore, in general, CCM is 
clinically not so problematic in a resting state. However, stresses 
such as liver transplantation, infection, and procedures like the 
insertion  of  TIPS,  can  convert  latent  to  overt  heart  failure. 
Indeed, with increasing liver transplantation, CCM-related heart 
failure is the third-leading cause of death after rejection and 
infection.
7,14 Therefore, the development of a precise screening 
test  and  assessment  of  CCM  severity  is  necessary  in  the 
management of cirrhosis.
Diastolic dysfunction is believed to be present in virtually all 
CCM patients, and a few reports have suggested that CCM 
could  be  diagnosed  with  simple  echocardiographic  diastolic 
dysfunction  indices  such  as  the  E/A  ratio  even  at  rest.
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Table  2.  Hemodynamics  and  cardiac  function  of  control  subjects  and  cirrhotic  patients  with  or  without  a  blunted  DSE  response
Controls  (n=8)
Liver  cirrhosis
with  normal  DSE  response  (n=53)
Liver  cirrhosis 
with  blunted  DSE  response  (n=18)
P-value
Basal  EF 61.8±7.9 66.3±8.5 71.5±7.0
‡ 0.022
Basal  EDV 85.4±18.8 84.9±29.1 86.3±14.7 0.987
Basal  ESV 31.9±9.7 29.7±14.4 24.7±7.6 0.476
Peak  EF 72.3±12.1 81.7±6.8 69.8±7.9
‡ <0.001
Peak  EDV 73.2±16.9 65.7±28.3 96.0±15.5
‡ <0.001
Peak  ESV 20.3±10.3 13.9±15.1 28.8±8.8
‡ <0.001
Basal  E/A  ratio 1.0±0.2 1.5±3.6
† 1.4±3.3
† <0.001
Peak  E/A  ratio 0.8±0.19 2.9±10.7
† 3.1±10.5
† <0.001
Basal  IVSD 0.9±0.1 0.7±0.2 0.8±0.1 0.526
Basal  PWD 0.9±0.6 0.8±0.1 0.9±0.1 0.589
Peak  IVSD 1.0±0.1 0.9±0.2 0.8±0.1 0.562
Peak  PWD 1.0±0.7 1.0±0.2 0.9±0.1 0.864
LA  index 27.3±9.8 29.0±9.7 28.0±10.9 0.867
∆  EF 16.7±10.0 24.8±15.9 -2.3±8.3
‡ <0.001
∆  EDV -13.7±14.6 -23.7±15.1 12.4±15.3
‡ <0.001
∆  ESV -37.8±30.6 -52.9±31.5 19.9±26.3
‡ <0.001
Basal  heart  rate 67.3±16.7 78.1±14.9 68.4±12.4
‡ 0.016
Peak  heart  rate 101.5±22.1 126.5±20.6 70.3±16.3
‡ <0.001
HRR  (%) 82.2±84.3 65.2±80.0
† 1.7±13.6
†‡ <0.001
DSE,  dobutamine  stress  echocardiography;  EF,  ejection  fraction;  EDV,  end-diastolic  volume;  ESV,  end-systolic  volume;  E/A  ratio, 
early/late  diastolic  flow  ratio;  IVSD,  interventricular  septal  diastolic  wall  thickness;  PWD,  Left  ventricular  posterior  wall  diastolic 
thickness;  ∆(delta),  amount  of  change;  HRR,  heart  rate  reserves.
† Comparison  with  control, 
‡ comparison  between  normal  and  blunted  DSE  response  group  in  cirrhosis. 
Additionally,  the  E/A  ratio  has  been  suggested  recently  as 
predictive  marker  for  survival  after  TIPS.
16  Our  study  also 
showed a significant difference in E/A ratio between controls 
and the total cirrhotic patients group. In addition, baseline and 
peak E/A ratio increased significantly according to Child-Pugh 
class as in previous studies, i.e., cirrhotic patients group showed 
definitive  diastolic  dysfunction  compared  with  the  normal 
control group.
17 However, in the present study, no significant 
difference  in  the  severity  of  diastolic  dysfunction  was  seen 
between subgroups of cirrhosis according to the DSE response. 
Many previous studies about diastolic dysfunction of CCM have 
a limitation because they only compared cirrhosis with normal 
controls. Diastolic dysfunction could be seen almost old ages. 
Indeed, some authorities contend that some degree of diastolic 
dysfunction is present in virtually every patient with cirrhosis.
18-21 
Therefore,  estimation  of  diastolic  dysfunction  with  simple 
echocardiography is not enough to differentiate true CCM 
patients from general cirrhotic patients. The most prominent 
feature of CCM is systolic dysfunction of LV compared with 
general cirrhotic patients. Hence, a provocative test for cardiac 
systolic dysfunction in liver cirrhosis patients based on CCM 
pathophysiology is needed as a screening test. Until now, many 
attempts to stress the ventricle by a physiological or pharmacological 
method have been made. In the case of the exercise test, reduced 
exercise capacity of cirrhotic patients related with aging process 
or other causes unrelated with cardiac function made it difficult 
to use as a provocation test.
15,22 While some previous studies 
used dobutamine on cirrhotic patients, it was just used to assess 
the risk of ischemic heart disease prior to a major operation; it 
was not proposed to estimate CCM.
23,24
Heart cell contractility is mainly determined by the stimulatory 
β-adrenergic receptor system. When stimulated by norepinephrine 
or other catecholamines, the β-adrenergic receptor-ligand 
complex couples with G-protein to stimulate membrane-bound 
adenylate  cyclase,  generating  cAMP  which  phosphorylates 
several  proteins  leading  to  intracellular  calcium  fluxes.  The 
calcium then causes actin-myosin cross-linking, and thus cellular 
contraction.
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receptor signalling pathways is the main pathogenesis of CCM; 
hence we assumed that ventricular systolic and diastolic function 
in a CCM patient would be blunted by norepinephrine or other 
catecholamines  stimulation  such  as  dobutamine.  Cardiac 
responses to environmental changes are probably even more 
important than how heart function at rest. Dobutamine is the 
most commonly used sympathomimetic agent for pharmacologic 
stress  testing  through  having  its  effect  of  direct  inotropic 
stimulation. This study is the first to apply DSE for differentiating 
CCM from general cirrhosis. We analyzed blunted and normal 
response cirrhosis patients according to left ventricular volume 
response after dobutamine infusion (Fig. 1, 2, 3). The criteria of 
abnormal LV volume response used in this study has already 
been proven as an independent prognostic value for cardiac event 
during major vascular surgery in the department of cardiology.
10 
In this study, according to these criteria, definitive blunted or 
inversed responses of LV during DSE were observed in 18 (25%) 
among  71  cirrhotic  patients.  Based  on  action  mechanism  of 
dobutamine, impaired cardiac response to dobutamine stimulation 
may  arise  from  defects  in  β-adrenergic  receptor  signalling 
pathways, implicated in CCM. It suggests that patients with 
blunted cardiac response to dobutamine may potentially have 
higher risk of sudden cardiac events, such as heart failure after 
major operation than those without impaired response. In fact, no 
characteristic difference in diastolic indices and liver profiles 
between normal and blunted DSE response group was observed 
in either the rest or stressed state. In other words, the latent risk of 
cardiac event cannot be detected with previously established 
liver profiles such as  Child-Pugh  score, MELD,  or diastolic 
cardiac indices. Hence, detecting patients with impaired 
β-adrenergic receptor signal transduction through DSE prior to a 
major operation could be helpful to prevent unexpected cardiac 
events. 
In  conclusion,  blunted  cardiac  response  to  dobutamine 
stimulation were frequently observed in cirrhotic patients, which 
may be attributed to defects in β-adrenergic receptor signalling 
pathways, which is one of major pathogenesis of CCM. 
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